388 related articles for article (PubMed ID: 29769444)
1. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.
Wang D; Aguilar B; Starr R; Alizadeh D; Brito A; Sarkissian A; Ostberg JR; Forman SJ; Brown CE
JCI Insight; 2018 May; 3(10):. PubMed ID: 29769444
[TBL] [Abstract][Full Text] [Related]
2. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
Sommermeyer D; Hudecek M; Kosasih PL; Gogishvili T; Maloney DG; Turtle CJ; Riddell SR
Leukemia; 2016 Feb; 30(2):492-500. PubMed ID: 26369987
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
5. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
7. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
8. Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products.
Logun M; Colonna MB; Mueller KP; Ventarapragada D; Rodier R; Tondepu C; Piscopo NJ; Das A; Chvatal S; Hayes HB; Capitini CM; Brat DJ; Kotanchek T; Edison AS; Saha K; Karumbaiah L
Cytotherapy; 2023 Jun; 25(6):670-682. PubMed ID: 36849306
[TBL] [Abstract][Full Text] [Related]
9. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
[TBL] [Abstract][Full Text] [Related]
10. Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models.
Csaplár M; Szöllősi J; Gottschalk S; Vereb G; Szöőr Á
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503109
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
12. [An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Chen GH; Huang HW; Wang Y; Liu HW; Xu LJ; Ma X; Xue SL; He XF; Wang Y; Gu B; Li CX; Qiu HY; Tang XW; Jin ZM; Miao M; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):148-152. PubMed ID: 29562451
[No Abstract] [Full Text] [Related]
13. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
14. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
Brown CE; Rodriguez A; Palmer J; Ostberg JR; Naranjo A; Wagner JR; Aguilar B; Starr R; Weng L; Synold TW; Tran V; Wang S; Reik A; D'Apuzzo M; Ressler JA; Zhou Y; Mendel M; Gregory PD; Holmes MC; Tang WW; Forman SJ; Jensen MC; Badie B
Neuro Oncol; 2022 Aug; 24(8):1318-1330. PubMed ID: 35100373
[TBL] [Abstract][Full Text] [Related]
15. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
[TBL] [Abstract][Full Text] [Related]
16. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
18. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma.
Wang D; Starr R; Chang WC; Aguilar B; Alizadeh D; Wright SL; Yang X; Brito A; Sarkissian A; Ostberg JR; Li L; Shi Y; Gutova M; Aboody K; Badie B; Forman SJ; Barish ME; Brown CE
Sci Transl Med; 2020 Mar; 12(533):. PubMed ID: 32132216
[TBL] [Abstract][Full Text] [Related]
19. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.
Beavis PA; Henderson MA; Giuffrida L; Mills JK; Sek K; Cross RS; Davenport AJ; John LB; Mardiana S; Slaney CY; Johnstone RW; Trapani JA; Stagg J; Loi S; Kats L; Gyorki D; Kershaw MH; Darcy PK
J Clin Invest; 2017 Mar; 127(3):929-941. PubMed ID: 28165340
[TBL] [Abstract][Full Text] [Related]
20. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
